Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Forma Therapeutics (FMTX) News Today

Forma Therapeutics logo
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Receives Average Rating of "Hold" from Brokerages
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) has earned an average recommendation of "Hold" from the six brokerages that are covering the company, Marketbeat.com reports. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The a
Forma Therapeutics Holdings, Inc. (FMTX)
4 Analysts Have This to Say About Forma Therapeutics Hldgs
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Given Average Rating of "Hold" by Brokerages
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) has earned a consensus rating of "Hold" from the six research firms that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation t
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics (NASDAQ:FMTX) Downgraded by HC Wainwright
HC Wainwright cut Forma Therapeutics from a "buy" rating to a "neutral" rating in a research report on Friday.
Forma Therapeutics: Rare Disease Play
Novo Nordisk To Acquire Forma Therapeutics - Quick Facts
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Short Interest Down 8.8% in August
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) was the recipient of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 1,650,000 shares, a drop of 8.8% from the July 31st total of 1,810,000 shares. Currently, 3.9% of the shares of the company are sold short. Based on an average daily volume of 542,500 shares, the short-interest ratio is presently 3.0 days.
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) to Post FY2022 Earnings of ($4.19) Per Share, Cantor Fitzgerald Forecasts
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) - Equities researchers at Cantor Fitzgerald raised their FY2022 earnings estimates for shares of Forma Therapeutics in a research note issued to investors on Monday, August 8th. Cantor Fitzgerald analyst P. Agrawal now anticipates that
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics (NASDAQ:FMTX) Price Target Cut to $33.00 by Analysts at Credit Suisse Group
Credit Suisse Group reduced their target price on shares of Forma Therapeutics to $33.00 in a report on Tuesday.
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX) Sees Significant Decline in Short Interest
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) was the recipient of a large drop in short interest in the month of June. As of June 30th, there was short interest totalling 1,910,000 shares, a drop of 33.9% from the June 15th total of 2,890,000 shares. Based on an average daily trading volume, of 593,000 shares, the short-interest ratio is currently 3.2 days. Currently, 4.6% of the company's stock are sold short.
Forma Therapeutics Holdings, Inc. stock logo
Cantor Fitzgerald Comments on Forma Therapeutics Holdings, Inc.'s FY2022 Earnings (NASDAQ:FMTX)
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) - Equities research analysts at Cantor Fitzgerald increased their FY2022 earnings per share (EPS) estimates for shares of Forma Therapeutics in a report issued on Monday, June 13th. Cantor Fitzgerald analyst P. Agrawal now anticipates t
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics Holdings, Inc. to Post FY2023 Earnings of ($3.47) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:FMTX)
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) - Cantor Fitzgerald issued their FY2023 earnings per share estimates for Forma Therapeutics in a report released on Monday, June 6th. Cantor Fitzgerald analyst P. Agrawal forecasts that the company will post earnings of ($3.47) per shar
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics (NASDAQ:FMTX) Lifted to "Buy" at Zacks Investment Research
Zacks Investment Research upgraded shares of Forma Therapeutics from a "hold" rating to a "buy" rating and set a $6.25 price target on the stock in a research report on Monday.
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics Holdings, Inc. to Post FY2022 Earnings of ($4.86) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:FMTX)
Forma Therapeutics Holdings, Inc. (NASDAQ:FMTX - Get Rating) - Equities researchers at Cantor Fitzgerald issued their FY2022 earnings estimates for Forma Therapeutics in a research note issued to investors on Monday, May 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post
Forma Therapeutics Holdings, Inc. stock logo
Forma Therapeutics' (FMTX) Overweight Rating Reaffirmed at Cantor Fitzgerald
Cantor Fitzgerald reiterated an "overweight" rating on shares of Forma Therapeutics in a report on Monday.
Forma Therapeutics: Q4 Earnings Insights
Get Forma Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FMTX and its competitors with MarketBeat's FREE daily newsletter.

Rare "crisis signal" triggers for third time in U.S. market (Ad)

A rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the market crashed 78% (the dot-com bust) and 89% (the Great Depression). Today, according to one of America's leading experts (who has predicted nearly every financial crisis of the last 25 years), what's coming next could soon crash the market by 50% or more, and keep it down for 10, 20, or even 30 years.

Click here for all the details. 

FMTX Media Mentions By Week

FMTX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

FMTX
News Sentiment

0.00

0.61

Average
Medical
News Sentiment

FMTX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

FMTX Articles
This Week

0

0

FMTX Articles
Average Week

Get Forma Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FMTX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:FMTX) was last updated on 12/22/2024 by MarketBeat.com Staff
From Our Partners